Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Zilurgisertib is an oral activin receptor-like kinase-2 (ALK2) inhibitor indicated to reduce the volume of total new heterotopic ossification in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva. It inhibits both wild-type ALK2 and the pathogenic R206H mutant form.
- Mechanism
- Curator reviewed · 4 references
FOP is a progressive disease caused by a monoallelic gain-of-function mutation in the activin A receptor, type I (ACVR1) gene, which codes the ALK2 type I receptor in the bone morphogenetic protein (BMP) signaling pathway. Patients with FOP have constitutively active ALK2 signaling that causes heterotopic ossification. Zilurgisertib is an oral, selective inhibitor of both wild-type ALK2 and pathogenic ALK2 (R206H mutation). Target engagement inhibits ALK2-mediated signaling and reduces endochondral bone formation.
- Primary indication
- Zilurgisertib is indicated to reduce the volume of total new heterotopic ossification (HO) in adults and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).Curator reviewed · 1 structured indication
- Formula / weight
- C30H38N4O3 · 502.659 g/mol (avg)
- First approval
- United States, 2026
- Code names
- INCB-000928 · NBU-928 free base
Resolves to
KPRPFTOLWQQUAV-OCVAFRRMSA-NSMILESNC1=NC=C(C=C1C(=O)NC12CCC(O)(CC1)CC2)C1=CC=C(C=C1)[C@@]12C[C@@H]1CN(C2)C1CCOCC1What you can answer from here — as of October 28, 2026
Which drugs share a target with Zilurgisertib, and which of those have an active Phase 3 trial?